CCCC
C4 Therapeutics, Inc.
-0.03 (-0.87%)3.42USD588K成交股數421M市值–本益比(近四季)12.0股價營收比+2.8%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 6.6M-8% | 6.2M+19% | 11.2M-27% | 6.5M-46% | 7.2M+138% | 5.2M-53% | 15.4M+477% | 12.0M+219% | 3.0M | 11.1M | 2.7M | 3.8M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 24.5M | 24.6M | 26.0M | 26.2M | 27.1M | 32.5M | 31.8M | 23.8M | 22.5M | 28.3M | 29.9M | 29.0M |
| 銷售管理費用 | 8.6M | 9.3M | 8.9M | 8.8M | 9.3M | 10.4M | 11.8M | 9.7M | 10.3M | 10.5M | 10.3M | 10.9M |
| 營業利益 | −26.4M-9% | −27.8M-26% | −34.4M+22% | −28.5M+33% | −29.2M-9% | −37.7M+36% | −28.2M-25% | −21.4M-41% | −32.2M | −27.8M | −37.6M | −36.2M |
| 營業利益率 | -397.9% | -451.6% | -306.4% | -441.0% | -402.9% | -728.4% | -183.9% | -178.6% | -1,060.2% | -251.2% | -1,410.2% | -963.8% |
| 稅後淨利 | −23.6M-10% | −25.1M-27% | −32.2M+30% | −26.0M+47% | −26.3M-7% | −34.6M+28% | −24.7M-31% | −17.7M-49% | −28.4M | −27.0M | −35.9M | −34.8M |
| 淨利率 | -355.9% | -408.5% | -286.4% | -402.6% | -363.7% | -667.8% | -160.6% | -147.6% | -933.2% | -244.2% | -1,348.4% | -925.2% |
| 稀釋 EPS | -0.18-51% | -0.20-60% | -0.44+26% | -0.37+42% | -0.37-10% | -0.50-9% | -0.35-52% | -0.26-63% | -0.41 | -0.55 | -0.73 | -0.71 |
| 稀釋股數 | 131M | 126M | 72.6M | 71.0M | 70.8M | 69.4M | 69.6M | 68.8M | 68.4M | 49.2M | 49.1M | 49.0M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 78.6M | 61.3M | 58.8M | 78.2M | 51.3M | 55.5M | 59.6M | 73.1M | 89.7M | 61.0M | 44.9M | 49.5M |
| 應收帳款 | 1.3M | 2.9M | 6.5M | 2.2M | 8.0M | 3.1M | 10.3M | 1.2M | 13.6M | 500K | 1.0M | 528K |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 359M | 329M | 265M | 297M | 320M | 350M | 376M | 381M | 398M | 333M | 375M | 396M |
| 有息負債 | – | – | – | – | – | – | – | – | – | 0.00 | 0.00 | 8.6M |
| 總負債 | 112M | 94.6M | 111M | 122M | 124M | 134M | 133M | 134M | 140M | 117M | 141M | 134M |
| 股東權益 | 247M | 234M | 154M | 174M | 195M | 216M | 243M | 247M | 258M | 216M | 234M | 262M |
| 負債比 | 31.2% | 28.8% | 41.8% | 41.3% | 38.9% | 38.2% | 35.5% | 35.2% | 35.2% | 35.1% | 37.7% | 33.7% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | 61.0M | 44.9M | 40.9M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −29.9M | – | – | −33.3M+84% | – | – | – | −18.1M | – | – | −33.1M |
| 資本支出 | – | 64K | – | – | 0.00 | – | – | – | 0.00 | – | – | 589K |
| 自由現金流 | – | −30.0M | – | – | −33.3M+84% | – | – | – | −18.1M | – | – | −33.7M |
| 折舊攤銷 | – | 404K | – | – | 456K | – | – | – | 448K | – | – | – |
| 買回庫藏股 | – | 200K | – | – | 155K | – | – | – | 109K | – | – | 94K |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -487.8% | – | – | -459.9% | – | – | – | -596.2% | – | – | -896.9% |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 35.9M | +1.0% | −105M | -292.1% | -1.27 | −99.3M |
| FY2024 | 35.6M | +71.4% | −105M | -296.0% | -1.52 | −65.3M |
| FY2023 | 20.8M | -33.3% | −132M | -638.3% | -2.67 | −109M |
| FY2022 | 31.1M | -32.1% | −128M | -412.2% | -2.62 | −111M |
| FY2021 | 45.8M | – | −83.9M | -183.2% | -1.82 | −88.2M |
| FY2020 | – | – | −66.3M | –% | -5.83 | −67.9M |
| FY2019 | – | – | −34.1M | –% | -31.03 | 54.3M |